RXi Pharmaceuticals Corporation Selected to Present at Cavendish Global Health Impact Forum

MARLBOROUGH, Mass., Sept. 7, 2016 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today it has been selected to present at the Cavendish Global Health Impact Forum co-hosted with the Arizona BioIndustry Association (AZBio)  taking place September 18-21, 2016 in Phoenix, Arizona.  The purpose of the Forum is to help family offices, foundations and impact investors develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.  To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, nonprofit organizations, private-sector and publicly traded companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.  A unique gathering of impact investors, Cavendish Impact Forums are hosted by leading institutions around the world and take place four times each year.

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

Michael Moffat, Cavendish co-founder and Chairman explains, "The theme of our Phoenix Forum is 'Innovation, Philanthropy and Impact Investing, Inspired for Impact.'  With the help of our expert advisors, we conduct a global search of research institutions, private-sector and publicly traded companies in order to identify organizations that meet the required standard of excellence.  The quality and originality of RXi Pharmaceuticals research and scientific insights in the development of novel RNAi-based therapeutics positions them well to make a major contribution in the development of potential new treatments for numerous diseases such as dermal and ocular scarring, ALS and cancer."

"We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach using our proprietary self-delivering RNAi compounds for the potential treatment of numerous diseases. Our mission is to improve patients' lives through the development of a new class of treatments based on our novel platform," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. "We welcome the chance to interact with many of world's most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.

About Cavendish Global

Cavendish Global provides family offices, foundations and impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides impact investors with a number of innovative resources, which includes Cavendish Health Impact Forums.  A unique gathering of leading impact investors, Cavendish Health Impact Forums take place four times each year. More information may be found at: http://cavendishglobal.com   

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs.  Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary RNAi (sd-rxRNA) platform and Samcyprone™, a topical immunomodulator. Our clinical development programs include RXI-109, an sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma.  RXi's robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com. 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact

RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
[email protected]  

Cavendish Global
Gwen Snyder
Vice President, Member Services
[email protected]

SOURCE RXi Pharmaceuticals Corporation

Related Links

http://www.rxipharma.com